title: Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome.
abstract: Prolonged prednisolone treatment for the initial episode of childhood nephrotic syndrome may reduce relapse rate, but whether this results from the increased duration of treatment or a higher cumulative dose remains unclear. We conducted a randomized, double-blind, placebo-controlled trial in 69 hospitals in The Netherlands. We randomly assigned 150 children (9 months to 17 years) presenting with nephrotic syndrome to either 3 months of prednisolone followed by 3 months of placebo (n=74) or 6 months of prednisolone (n=76), and median follow-up was 47 months. Both groups received equal cumulative doses of prednisolone (approximately 3360 mg/m(2)). Among the 126 children who started trial medication, relapses occurred in 48 (77%) of 62 patients who received 3 months of prednisolone and 51 (80%) of 64 patients who received 6 months of prednisolone. Frequent relapses, according to international criteria, occurred with similar frequency between groups as well (45% versus 50%). In addition, there were no statistically significant differences between groups with respect to the eventual initiation of prednisolone maintenance and/or other immunosuppressive therapy (50% versus 59%), steroid dependence, or adverse effects. In conclusion, in this trial, extending initial prednisolone treatment from 3 to 6 months without increasing cumulative dose did not benefit clinical outcome in children with nephrotic syndrome. Previous findings indicating that prolonged treatment regimens reduce relapses most likely resulted from increased cumulative dose rather than the treatment duration.
authors.affiliation: Department of Pediatrics, Division of Nephrology, Erasmus University Medical Centre—Sophia Children’s Hospital, Rotterdam, The Netherlands. n.teeninga@erasmusmc.nl
authors.forename: Nynke
authors.initials: N
authors.lastname: Teeninga
authors.forename: Joana E
authors.initials: JE
authors.lastname: Kist-van Holthe
authors.forename: Nienske
authors.initials: N
authors.lastname: van Rijswijk
authors.forename: Nienke I
authors.initials: NI
authors.lastname: de Mos
authors.forename: Wim C J
authors.initials: WC
authors.lastname: Hop
authors.forename: Jack F M
authors.initials: JF
authors.lastname: Wetzels
authors.forename: Albert J
authors.initials: AJ
authors.lastname: van der Heijden
authors.forename: Jeroen
authors.initials: J
authors.lastname: Nauta
mesh_terms: D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D009404:Nephrotic Syndrome / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage*; D055502:Secondary Prevention
chemical_list: D005938:Glucocorticoids; D011239:Prednisolone